Redeye comments on Gasporox’s convertible debt financing.
Redeye provides an update on Gasporox following its Q3 2024 report, which was below expectations but continued net sales growth and positive...
Redeye notes that Gasporox's report came in below Redeye Estimates (RRe) across the board while producing its highest net sales in Q3 yet.
Redeye states that Q2 2024 was solid, beating estimates across the board.
Redeye states the report was solid, beating its net sales forecast by 25% and growing 19% y/y despite a tough comparison quarter and showing...
Gasporox’s results closely align with RRe expectations, showing seven quarters of positive EBITDA driven by sales from VialArch, GPX1500, an...
Redeye states the report aligned with its estimates, and Gasporox has now produced positive EBITDA seven consecutive quarters in a row, thus...
Redeye states that net sales were slightly higher than expected, but OPEX was also higher.
Redeye comments on Gasporox's Q4 report, which was in line with estimates.
Gasporox has secured a SEK9.1m order for its VialArch product from MaxCann, with deliveries scheduled throughout 2024 in three batches.
Redeye provides an update on Gasporox after its Q3 2023 report.
Redeye comments on Gasporox Q3 2023 report which came in below estimates.
Redeye provides a quick comment on Gasporox’s AutoMap agreement worth SEK3m with Weber Maschinenbau GmbH (Weber), a distinguished German man...
Redeye provides an update after Gasprox’s Q2’23 report.
Redeye comments on Gasporox’s Q2’23 report, which was significantly stronger than expected on all items.
Redeye comments on Gasporox Q1'23 report which beat expectations across the board.
Gasporox beat our expectations by 34% on the top line with positive quarterly EBITDA.
Redeye comments on Gasporox Q4'22 report which came in lighter than expected.
Redeye states that the Q4 report was weaker than expected with net sales coming in 43% lower than expected and EBITDA 98% lower than expecte...
Redeye states the Q3 report was strong across the board.
Redeye states Gasporox report was strong with beats accross the board.
Gasprox announced yesterday that it plans to issue a convertible note worth SEK 5.
Redeye initiates coverage on Gasporox, a manufacturer of laser-based quality assurance and testing equipment.
